ARDX Jun 2024 6.000 call
| Previous Close | 0.5000 |
| Open | 0.7000 |
| Bid | 1.3000 |
| Ask | 3.2000 |
| Strike | 6.00 |
| Expire Date | 2024-06-28 |
| Day's Range | 0.7000 - 1.3000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 95 |
GlobeNewswireArdelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Confere
Simply Wall St.When Will Ardelyx, Inc. (NASDAQ:ARDX) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
- GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut
